PATENT CLAIM ANALYSIS

Application Number: 16117372
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "093710"]

Abstract:
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.

Claim (Index 20):
The method according  claim 19 , wherein the hematologic malignancy is acute myeloid leukemia, chronic myelogenous leukemia (CML), accelerated CML, CML blast phase (CML-BP), acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, follicular lymphoma, mantle cell lymphoma, B-cell lymphoma, T-cell lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, myelodysplastic syndromes (MDS), refractory anemia (RA), RA with ringed sideroblasts, RA with excess blasts (RAEB), RAEB in transformation, or a myeloproliferative syndrome.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 96.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16034123', '16034064', '15868469', '15620411', '15868459']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7304962264435619
- 35 USC 102 Novelty (BERT): 0.6217789827843422
- Combined Prediction Score: 0.71962450207764
- Mean Citation Score: 381.753286
- Max Citation Score: 695.2320599999997
- Similarity Product: 469.8626658476901

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test